Abatacept

Drug Profile

Abatacept

Alternative Names: BMS-188667; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; Orencia; Orencia IV; Orencia SC

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Medical Center Groningen; University of Michigan
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Preregistration Psoriatic arthritis
  • Phase III Lupus nephritis; Sjogren's syndrome
  • Phase II Diffuse scleroderma; Nephrotic syndrome
  • Preclinical Inflammation
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 31 Jan 2017 Phase-III clinical trials in Sjogren's syndrome in Japan (IV) (Ono Pharmaceutical pipeline, January 2017)
  • 22 Dec 2016 U.S. Patent and Trademark Office’s Patent Trial and Appeal Board upholds validity of U.S. Patent No. 8 476 239, related to ORENCIA®
  • 01 Dec 2016 Phase-III clinical trials in Sjogren's syndrome in Puerto Rico (SC) after December 2016 (NCT02915159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top